APA (7th ed.) Citation

X, R., S, N., K, P., G, D., M, F., S, K., . . . S, P. (2024). Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease. Journal of Crohn's & colitis, 18(5), 679. https://doi.org/10.1093/ecco-jcc/jjad188

Chicago Style (17th ed.) Citation

X, Roblin, et al. "Higher Serum Infliximab Concentrations Following Subcutaneous Dosing Are Associated with Deep Remission in Patients with Inflammatory Bowel Disease." Journal of Crohn's & Colitis 18, no. 5 (2024): 679. https://doi.org/10.1093/ecco-jcc/jjad188.

MLA (9th ed.) Citation

X, Roblin, et al. "Higher Serum Infliximab Concentrations Following Subcutaneous Dosing Are Associated with Deep Remission in Patients with Inflammatory Bowel Disease." Journal of Crohn's & Colitis, vol. 18, no. 5, 2024, p. 679, https://doi.org/10.1093/ecco-jcc/jjad188.